Individuals living with motor neurone disease (MND) in the United Kingdom are being denied access to a breakthrough treatment, tofersen. This comes despite the biotech firm Biogen is supplying the drug free of charge while it undergoes formal evaluation for standard use within the National Health Service (NHS).
The innovative drug, approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), targets a rare genetic form of MND. It has been hailed as the first effective therapy in decades for this condition.
